Pfizer vaults into CD47 arena, buying Trillium for $2.3 bill...

Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a 'don't eat me' signal that protects cancer cells from being attacked by the immune system.

Gilead cleared to restart trials of CD47 drug magrolimab

Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centrepiece of its $4.9 billion 

2nd Macrophage-directed Therapies Summit

Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond

ALX Oncology cancer drug claims two FDA fast-track reviews